AI assistant
Rua Bioscience Limited — Capital/Financing Update 2024
Nov 17, 2024
66262_rns_2024-11-18_079eb135-a5b3-4c9d-9b7b-b23e02c0410a.pdf
Capital/Financing Update
Open in viewerOpens in your device viewer
MARKET UPDATE
==> picture [132 x 77] intentionally omitted <==
FOR PUBLIC RELEASE
NZX Limited Wellington
18 November 2024
Revenue continues to grow
Rua Bioscience Limited (“RUA”) is pleased to report continued month-on-month growth in sales revenue, as seen in our latest figures below (unaudited). With our products now available in three key markets - Aotearoa NZ, Australia and Germany - Rua is establishing a strong national and international presence.
==> picture [359 x 216] intentionally omitted <==
----- Start of picture text ----- 128 k122 k82 k23 k 24 k16 k6 kApr-24 May-24 Jun-24 Jul-24 Aug-24 Sep-24 Oct-24Revenue – NZ$000Jul 24 – Oct 24 are unaudited figures----- End of picture text -----
Looking ahead, we are launching products in the UK within the next month, a move that we anticipate will further accelerate our strong growth trajectory. And we will also have new products in Aotearoa and Germany before the end of this year.
Our current revenue trajectory along with new product offerings in key markets give us confidence in our business plan. We are forecasting revenue over $3mill by the end of FY25.
ENDS
The person who authorised this announcement:
Paul Naske Chief Executive Officer [email protected] +64 21 445154
PO Box 1387, Gisborne 4040, Aotearoa New Zealand | 0800 RUABIO | www.ruabio.com